WTx-101

WTx-101 is an experimental therapeutic candidate being developed by Window Therapeutics, currently in the lead optimization stage. It is built upon the company's proprietary BAM (Bispecific Antibody-drug conjugate-like Molecule) platform, which aims to create next-generation antibody-drug conjugates (ADCs) with bispecific targeting capabilities. This dual-targeting approach is intended to increase the precision of payload delivery to specific cells, potentially improving the therapeutic index compared to conventional monospecific ADCs. While the specific molecular target (placeholder 'Target 2') and the primary disease indications have not been publicly disclosed, the technology is typically applied in the field of oncology to target tumor-associated antigens.